Application of fractional factorial designs to study drug combinations

Statistics in Medicine

Volumn 32, Issue 2, 2013, Pages 307-318

  Jaynes, Jessica ^a   Ding, Xianting ^a   Xu, Hongquan ^a   Wong, Weng Kee ^a   Ho, Chih Ming ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blocking; Drug combination; Effect aliasing; Experimental design; Fractional factorial design; Herpes simplex virus

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; GAMMA INTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; DRUG COMBINATION; DRUG INTERACTION; EXPERIMENTAL STUDY; FACTORIAL DESIGN; FRACTIONAL FACTORIAL DESIGN; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ACYCLOVIR; ANTIVIRAL AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERON-GAMMA; MODELS, STATISTICAL; RIBAVIRIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871347956     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5526     Document Type: Article

References (34)

1. McGrath N, Anderson NE, Croxson MC, Powell KF. Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. Journal of Neurology Neurosurgery and Psychiatry 1997; 63(3):321-326.
2. Zuckerman RA, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, Zuniga R, Magaret AS, Wald A, Corey L, Celum C. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-e1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. Journal of Infectious Diseases 2007; 196(10):1500-1508.
3. Malkin JE, Morand P, Malvy D, Ly TD, Chanzy B, de Labareyre C, El Hasnaoui A, Hercberg S. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sexually Transmitted Infections 2002; 78(3):201-203.
4. Scoular A, Norrie J, Gillespie G, Mir N, Carman WF. Longitudinal study of genital infection by herpes simplex virus type 1 in western Scotland over 15 years. British Medical Journal 2002; 324(7350):1366-1367.
5. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA-Journal of the American Medical Association 2006; 296(8):964-973.
6. Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clinical Infectious Diseases 1995; 20(2):414-420.
7. Rong Q, Alexander TS, Koski GK, Rosenthal KS. Multiple mechanisms for HSV-1 induction of interferon alpha production by peripheral blood mononuclear cells. Archives of Virology 2003; 148(2):329-344.
8. Andersen JH, Jenssen H, Gutteberg TJ. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Research 2003; 58(3):209-215.
9. Biswas S, Sukla S, Field HJ. Drug resistance mutations in HSV-1 UL5 selected using a helicase-primase inhibitor: frequency and effects on virus growth and pathogenicity. Antiviral Research 2009; 82(2):A68-A69.
10. Gray R, Wilson D. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. New England Journal of Medicine 2010; 362(18):1740-1742.
11. De Clercq E. Antiviral drugs in current clinical use. Journal of Clinical Virology 2004; 30(2):115-133.
12. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. American Association for Cancer Research 2010; 70(2):440-445.
13. Straetemans R, O'Brien T, Wouters L, Dun JV, Janicot M, Bijnens L, Burzykowski T, Aerts M. Design and analysis of drug combination experiments. Biometrical Journal 2005; 47:299-308.
14. Wong PK, Yu F, Shahangian A, Cheng G, Sun R, Ho CM. Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proceedings of the National Academy of Sciences 2008; 105(13):5105-5110.
15. Tsutsui H, Valamehr B, Hindoyan A, Qiao R, Ding X, Guo S, Witte ON, Liu X, Ho CM, Wu H. An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nature Communications 2011; 2(167):1-8. DOI: 10.1038/ncomms1165.
16. Ding X, Sanchez DJ, Shahangian A, Al-Shyoukh I, Cheng G, Ho CM. Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. International Journal of Nanomedicine 2012; 7:2281-2292.
17. Al-Shyoukh I, Yu F, Feng J, Yan K, Dubinett S, Ho CM, Shamma JS, Sun R. Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Systems Biology 2011; 5(88):1-17. DOI: 10.1186/1752-0509-5-88.
18. Box GEP, Hunter WG, Hunter JS. Statistics for Experimenters, (2nd edn). Wiley: New York, 2005.
19. Box GEP, Draper NR. Response Surfaces, Mixtures, and Ridge Analyses, (2nd edn). Wiley: New York, 2007.
20. Myers RH, Montgomery DC, Anderson-Cook CM. Response Surface Methodology: Process and Product Optimization Using Designed Experiments, (3rd edn). Wiley: New York, 2009.
21. Wu CFJ, Hamada M. Experiments: Planning, Analysis and Parameter Design Optimization, (2nd edn). Wiley: New York, 2009.
22. Montgomery DC. Design and Analysis of Experiments, (7th edn). Wiley: New York, 2009.
23. Mee RW. A Comprehensive Guide to Factorial Two-Level Experimentation, Springer: New York, 2009.
24. n-p designs. Technometrics 1997; 39:298-307.
25. Sitter RR, Chen J, Feder M. Fractional resolution and minimum aberration in blocked factorial designs. Technometrics 1997; 39:382-390.
26. n-m designs. Annals of Statistics 1999; 27:1948-1973.
27. Cheng SW, Wu CFJ. Choice of optimal blocking schemes in two-level and three-level designs. Technometrics 2002; 44:269-277.
28. Xu H. Blocked regular fractional factorial designs with minimum aberration. Annals of Statistics 2006; 34:2534-2553.
29. Xu H, Lau S. Minimum aberration blocking schemes for two- and three-level fractional factorial designs. Journal of Statistical Planning and Inference 2006; 136:4088-4118.
30. Xu H, Mee RW. Minimum aberration blocking schemes for 128-run designs. Journal of Statistical Planning and Inference 2010; 140:3213-3229.
31. Xu H. A catalogue of three-level regular fractional factorial designs. Metrika 2005; 62:259-281.
32. Xu H, Wong A. Two-level nonregular designs from quaternary linear codes. Statistica Sinica 2007; 17:1191-1213.
33. Xu H. Algorithmic construction of efficient fractional factorial designs with large run sizes. Technometrics 2009; 51:262-277.
34. Ryan K, Bulutoglu D. Minimum aberration fractional factorial designs with large N. Technometrics 2010; 52(2):250-255.